DaVita EBITDA 2010-2025 | DVA

DaVita EBITDA for the quarter ending March 31, 2025 was $0.615B, a 8.28% decline year-over-year.

  • DaVita 2024 EBITDA was 2.814B, a 19.85% increase from 2023.
  • DaVita 2023 EBITDA was 2.348B, a 13.35% increase from 2022.
  • DaVita 2022 EBITDA was 2.072B, a 16.4% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

DaVita EBITDA 2010-2025 | DVA

  • DaVita 2024 EBITDA was 2.814B, a 19.85% increase from 2023.
  • DaVita 2023 EBITDA was 2.348B, a 13.35% increase from 2022.
  • DaVita 2022 EBITDA was 2.072B, a 16.4% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Quest Diagnostics (DGX)$18.3B
Encompass Health (EHC)$10.4B
Chemed (CHE)$8.5B
Option Care Health (OPCH)$5.3B
Elanco Animal Health (ELAN)$4.2B
RadNet (RDNT)$3.7B
Amedisys (AMED)$3B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$1.8B
Astrana Health (ASTH)$1.6B
U.S Physical Therapy (USPH)$1B
Pennant (PNTG)$907M
Aveanna Healthcare Holdings (AVAH)$886M
Atai Life Sciences (ATAI)$294M
Daxor (DXR)$36M
Ontrak (OTRK)$6M
MEDIROM Healthcare Technologies (MRM)$4M
Psychemedics (PMD)$0M